GlassScriptPhysician profile
Raechele Holcomb Simpson
NPI 1225400997
$7,719.78
in general payments reported to CMS, 2019-2025
35 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,109 · 2022: $1,851 · 2023: $967 · 2024: $1,156 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $1,785.35 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Boston Scientific Corporation | $1,697.49 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $1,272.30 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.93 | 2021-2025 | Relistor |
| Abbvie INC. | $417.72 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $276.14 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $274.90 | 2021 | |
| Collegium Pharmaceutical, INC. | $255.61 | 2021-2025 | Belbuca |
| Amgen INC. | $251.84 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $163.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.71 | 2022 | |
| Grt US Holding, INC. | $91.50 | 2021 | |
| Medtronic, INC. | $84.29 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Pfizer INC. | $59.69 | 2025 | |
| Redhill Biopharma INC. | $57.57 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $45.35 | 2025 | Movantik |
| Biodelivery Sciences International, INC. | $38.38 | 2021 | |
| Nevro Corp. | $38.33 | 2022-2023 | Senza |
| Virtus Pharmaceuticals LLC | $34.09 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.56 | 2023 | Onpattro |
| Averitas Pharma INC. | $27.84 | 2025 | Qutenza |
| Ibsa Pharma INC. | $27.18 | 2021 | |
| Horizon Therapeutics Plc | $26.54 | 2021 | |
| Lundbeck LLC | $25.46 | 2022 | |
| Almatica Pharma LLC | $22.52 | 2023 | Gralise |
| Fidia Pharma USA INC. | $21.30 | 2025 | Hymhyn |
| Abbott Laboratories | $20.15 | 2025 | Immunalysis Corporation |
| Pacira Therapeutics, INC. | $18.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.13 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.03 | 2025 | |
| Bioventus LLC | $15.01 | 2021 | |
| Biotissue Holdings INC. | $14.78 | 2024 | |
| Avanos Medical | $12.70 | 2023 | Coolief* Cooled Radiofrequency |
| Uswm, LLC | $12.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raechele Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.